Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Mark Verrill.

Newcastle AuthorsTitleYearFull text
Dr Mark Verrill
Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study2021
Dr Mark Verrill
Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage2020
Anantha Madhavan
Alexander Phillips
Arul Immanuel
Dr Mark Verrill
Professor Michael Griffin
et al.
Surgical management of gastric gastrointestinal tumours: Comparison of local and radical resection2018
Dr David Jamieson
Dr Nicola Sunter
Sara Muro
Dr Nicola Cresti
Julieann Sludden
et al.
Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide2017
Dr Nicola Cresti
Dr Despina Televantou
Dr David Jamieson
Dr Mark Verrill
Professor Alan Boddy
et al.
Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cance2016
Dr David Jamieson
Dr Jo Lee
Dr Nicola Cresti
Melanie Griffin
Julieann Sludden
et al.
Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil2014
Dr Mark Verrill
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib2011
Dr David Jamieson
Dr Nicola Cresti
Julieann Sludden
Melanie Griffin
Nahed Hawsawi
et al.
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy2011
Dr Chris Plummer
Dr Mark Verrill
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials2010
Julieann Sludden
Melanie Griffin
Mike Cole
Dr Mark Verrill
Dr David Jamieson
et al.
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide2010
Dr Mark Verrill
Capecitabine and vinorelbine in metastatic breast cancer2009
Dr David Jamieson
Dr Nicola Cresti
Dr Mark Verrill
Professor Alan Boddy
Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma2009
Dr Chris Plummer
Dr Mark Verrill
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk2009
Dr Fathi Azribi
Dr Petra Dildey
Dr John Wilsdon
Dr Mark Verrill
Imatinib in gastrointestinal stromal tumour (GIST): Northern cancer network experience2009
Professor Ruth Plummer
Professor Alan Boddy
Melanie Griffin
Dr Mark Verrill
A phase I and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies2008
Dr Mark Verrill
Dr Chris Plummer
DEVELOPMENT AND IMPLEMENTATION OF NEW UK NATIONAL CANCER RESEARCH INSTITUTE (NCRI) GUIDELINES FOR PREVENTING AND MANAGING CARDIAC EVENTS WITH TRASTUZUMAB2008
Dr Elizabeth McIntyre
Dr Mark Verrill
Dr Richard Quinton
Professor Simon Pearce
Lesson of the week: Unrecognised severe hypovitaminosis D2008
Dr Mark Verrill
UK TACT trial results - does everyone need adjuvant taxanes?2008
Dr Mark Verrill
A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer2007
Amina Razak
Dr Beate Haugk
Dr Mark Verrill
Desmoplastic small round-cell tumor of the pancreas2007
Dr Mark Verrill
Hormonal therapy for postmenopausal breast cancer: the science of sequencing2007
Dr Jo Lee
Dr Mark Verrill
Julieann Sludden
Melanie Griffin
Sharon Erb
et al.
Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer2007
Dr Mark Verrill
Dr Steven O'Reilly
TEXAS (Taxotere (R) EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC2007
Dr Jo Lee
Julieann Sludden
Professor Alan Boddy
Dr Mark Verrill
Investigation of multi-drug resistance 1 (MDR1) and cytochrome P4502C8 (CYP2C8) pharmacogenetics on outcome from treatment of advanced breast cancer using paclitaxel in a UK national trial of a weekly versus 3-weekly schedule.2006
Professor Alan Boddy
Professor Ruth Plummer
Julieann Sludden
Melanie Griffin
Dr Mark Verrill
et al.
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules2005
Professor Jacqueline Rodgers
Dr Rachel Morse
Katherine Kendell
Dr Mark Verrill
An investigation into the psychometric properties of the Hospital Anxiety and Depression Scale in patients with breast cancer2005
Dr Mark Verrill
Cost-effectiveness (C-E) of oral ibandronate compared with intravenous (iv) zoledronic acid or iv generic pamidronate in patients with metastatic bone disease from breast cancer in the UK2005
Dr Mark Verrill
Duncan Cameron
Externally audited results of the international breast cancer dose-intensity study (IBDIS)2005
Dr Mark Verrill
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer2005
Dr Mark Verrill
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2)2005
Ching Ng
Dr Mark Verrill
Jessica Hodge
Phase II, open label study of SB-715992 (Ispinesib) in subjects with advanced or metastatic breast cancer2005
Dr Mark Verrill
Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study2005
Dr Mark Verrill
Duncan Cameron
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: A randomized trial2004
Dr Mark Verrill
Effect of tandem high-dose chemotherapy (HDC) on long-term complete remissions (LTCR) in metastatic breast cancer (MBC), compared to conventional dose (CDC) in patients (pts) who were not selected on the basis of response to prior C: Mature results of the IBDIS-I2004
Dr Mark Verrill
Evidence that durable complete remissions (DCR) of metastatic breast cancer (MBC) following high-dose chemotherapy (HDC) are not artefacts of selection by response: mature results of the International Breast Cancer Dose Intensity Randomised and Pilot Studies (IBDIS-I)2004
Dr Mark Verrill
Lessons from a positive randomized trial of high-dose chemotherapy in metastatic breast cancer: Learn from our mistakes, build on our successes, drain the bathwater, hold the baby2004
Dr A Stewart
Dr Mark Verrill
Trilostane, an effective signal transduction inhibitor for advanced ER plus ve and ER-ve post-menopausal breast cancer2004
Dr Mark Verrill
Professor Jacqueline Rodgers
Dr Rachel Morse
Katherine Kendell
Adjuvant taxane and block sequential anthracycline regimens predict post treatment cognitive morbidity2003
Professor Jacqueline Rodgers
Dr Rachel Morse
Dr Mark Verrill
Katherine Kendell
Cognitive functioning in women following adjuvant treatment for breast cancer2003
Dr A Stewart
Dr Mark Verrill
Multi-center clinical trials of trilostane (modrenal) for advanced breast cancer in post-menopausal women2003
Dr Rachel Morse
Professor Jacqueline Rodgers
Dr Mark Verrill
Katherine Kendell
Neuropsychological functioning following systemic treatment in women treated for breast cancer: A review2003
Dr Mark Verrill
Professor Alan Boddy
Julieann Sludden
Kevin Fishwick
Lynsey Robson
et al.
Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors2003
Dr Mark Verrill
Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma2003
Dr Mark Verrill
Preliminary results of a phase II study of intravenous vinflunine as second line therapy in patients with metastatic breast cancer after anhracycline-taxane based regimen failure2003
Dr Mark Verrill
A guideline for the management of gastrointestinal stromal tumour (GIST)2002
Dr Mark Verrill
A Phase I trial assessing the pharmacokinetics and tolerability of ZD1839 ('Iressa') in hepatically impaired patients with solid tumours2002
Professor Alan Boddy
Dr Mark Verrill
Julieann Sludden
Kevin Fishwick
Lynsey Robson
et al.
Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study2002
Professor Ruth Plummer
Dr Mark Verrill
Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin in patients with advanced malignancies2002
Dr Andrew Hughes
Dr Paula Calvert
Dr Ashraf Azzabi
Professor Ruth Plummer
Melanie Griffin
et al.
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma2002
Dr Andrew Hughes
Dr Ashraf Azzabi
Professor Ruth Plummer
Dr Jane Margetts
Kevin Fishwick
et al.
A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta (R), multitargeted antifolate).2001
Dr Mark Verrill
Anthracyclines in breast cancer: therapy and issues of toxicity2001
Professor Alan Boddy
Dr Mark Verrill
Julieann Sludden
Melanie Griffin
Kevin Fishwick
et al.
Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate2001
Dr Mark Verrill
Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study2000
Dr Mark Verrill
Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma2000
Dr Mark Verrill
Susceptibility of fibromatosis cells in short-term culture to ifosfamide: A possible experimental treatment in clinically aggressive cases1999